Monitoring urine proteins to predict early recurrence of liver cancer after surgery
Official title: Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
Run by Zhujiang Hospital · NCT06861114 · Data updated 2026-11-12
This study is testing if checking urine proteins can help doctors spot early signs of liver cancer coming back after surgery, so they can start treatment sooner for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 38 (estimated) |
| Sponsor | Zhujiang Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | February 20, 2025 |
| Main results expected | December 20, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | March 6, 2025 |
| Trial ID | NCT06861114 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with hepatocellular carcinoma at BCLC staging 0, A, or B who are eligible for radical surgical resection and have not undergone prior antitumor therapy.
✕Probably not a fit
Patients with renal or urologic diseases, multiple tumors, or those who have previously received anti-tumor therapies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of urine proteomics to monitor patients after radical surgery for hepatocellular carcinoma (HCC) to predict early recurrence of the disease. It aims to validate a model that assesses minimal residual disease (MRD) status through urine samples, potentially identifying recurrences sooner than traditional imaging methods. The study also explores the feasibility of using these findings to guide adjuvant treatment strategies in the postoperative period, offering a novel approach to early intervention for HCC patients.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of liver cancer recurrence, allowing for timely interventions that may improve patient outcomes.
How similar studies have gone: While the use of urine proteomics in cancer monitoring is an emerging field, this specific approach to HCC recurrence is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with hepatocellular carcinoma whose tumor stage at the time of initial diagnosis is consistent with BCLC staging 0/stage A/stage B, who can undergo radical surgical resection, and who have not received other antitumor therapy preoperatively. Exclusion Criteria: * Unable to provide specimens for testing such as urine proteomics; patients with a previous diagnosis of renal or urologic disease, two or more tumors at the same time; patients with non-primary foci of liver disease. Previously received anti-tumor therapy such as targeted immunotherapy.
Where it's running
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
AI-guided treatment choices for advanced liver cancer
Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.
-
Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer
Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
MRI plus diffusion and CEST imaging to map liver cancer and its immune environment
This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.
-
Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC
This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.